Antileukotrienes and asthma: Alternative or adjunct to inhaled steroids?

Cleveland Clinic Journal of Medicine

Volumn 65, Issue 10, 1998, Pages 519-526

  Kavuru, Mani S ^b   Subramony, Revathi ^a   Vann, Ana R ^c  

^a METROHEALTH MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CARBAMAZEPINE; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PHENYTOIN; PROPRANOLOL; STEROID; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOOD DRUG INTERACTION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; PATIENT COMPLIANCE; REVIEW;

EID: 0032448252     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.10.519     Document Type: Review

References (25)

1. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997. Publication No. 97-4051.
2. Dekker FW, Dieleman FE, Kaptein AA, Mulder JD. Compliance with pulmonary medication in general practice. Eur Resp J 1993; 6:886-890.
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157:51-553.
4. Lundgren R, Soderberg M, Horsted P, Stenling R. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J 1988; 1:883-889.
5. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1-13.
6. O'Bryne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127:472-480.
7. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059-1066.
8. Israel E, Cohn I, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996; 275:931-936.
9. Zafirlukast for asthma. Med Lett Drugs Ther 1996; 38:111-112.
10. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 7997; 126:177-183.
11. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455-457.
12. Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss Syndrome. Chest 1995; 108:320-323.
13. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicenter randomized double-blind trial. Arch Intern Med 1998; 158:1213-1220.
14. Leff JA, Israel E, Noonan MJ, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids in asthmatic patients while maintaining clinical stability (abstract). Am J Respir Crit Care Med 1997; 155:A976.
15. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187-1194.
16. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6-to 14-year-old children. The Pediatric Montelukast Study Group. JAMA 1998; 279:1181-1186.
17. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154:1349-1352.
18. Bootsma GP, Dekhuijzen PNR, Festen J, Mulder PG, van Herwaarden CL. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax 1995; 50:1044-1050.
19. Fischer AR, McFadden CA, Frantz R, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness, in asthmatic subjects. Am J Respir Crit Care Med 1995; 152 (4 pt 1):1203-1207.
20. Olivieri D, Chetta A, Donno MD, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155:1864-1871.
21. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152:1467-1473.
22. Nelson HS, Bernstein IL, Fink J, et al. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Chest 1998; 113:1264-1271.
23. Meltzer SS, Rasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respr Crit Care Med 1996; 153:931-935.
24. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147-152.
25. Schwartz HJ, Petty T, Dube LM, et al. A randomized controlled trial comparing zileuton with theophyllme in moderate asthma. Arch Intern Med 1998; 158:141-148.